1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship

Ting Liang; Xiangyang Sun; Wenhong Li; Guihua Hou; Feng Gao

doi:10.3389/fphar.2021.661173

1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship

Front Pharmacol. 2021 Jun 11:12:661173. doi: 10.3389/fphar.2021.661173. eCollection 2021.

Authors

Ting Liang¹, Xiangyang Sun², Wenhong Li³, Guihua Hou¹, Feng Gao¹

Affiliations

¹ Key Laboratory for Experimental Teratology of the Ministry of Education and Biomedical Isotope Research Center, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
² Department of Interventional Radiology, Qilu Hospital of Shandong University, Jinan, China.
³ Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

Abstract

Lung cancer is the most common malignancy and leads to around one-quarter of all cancer deaths. Great advances have been achieved in the treatment of lung cancer with novel anticancer agents and improved technology. However, morbidity and mortality rates remain extremely high, calling for an urgent need to develop novel anti-lung cancer agents. 1,2,3-Triazole could be readily interact with diverse enzymes and receptors in organisms through weak interaction. 1,2,3-Triazole can not only be acted as a linker to tether different pharmacophores but also serve as a pharmacophore. This review aims to summarize the recent advances in 1,2,3-triazole-containing compounds with anti-lung cancer potential, and their structure-activity relationship (SAR) together with mechanisms of action is also discussed to pave the way for the further rational development of novel anti-lung cancer candidates.

Keywords: anticancer; hybrid molecules; lung cancer; structure–activity relationship; triazole.

Publication types

Review